Aim. The aim of the paper was to examine the impact of disease duration and administered therapy on the development of metabolic syndrome (MetS) in patients with systemic lupus erythematosus (SLE). Material and methods. This study involved 55 patients (50 females and 5 males) with the diagnosis and 49 healthy controls of similar age. MetS was defined according to modified NCEP-ATP III diagnostic criteria, and obesity was defined by body mass index BMI > 30. Results. In the group of SLE patients with MetS, there were 23 individuals (41.82%). In the control group, there were 10 (20.4%) patients with MetS. There were significantly more SLE patients with MetS in comparison to the controls (p = 0.04). Duration of the disease in the group with MetS was longer in comparison to those without MetS, but it was not statistically significant (15.35 ± 10.26 vs 10.44 ± 7.88, p = 0.073). The study confirmed that there is a moderate association (CC = 0.355) between disease duration and number of MetS parameters, however, this dependency was not statistically significant (p = 0.439). In the group without MetS, there were statistically more patients treated with antimalarial drugs monotherapy (p = 0.023). It has been found that the patients with MetS were treated with corticosteroid therapy longer than those without MetS, but it was not statistically significant (153.57 ± 103.34 vs 114.75 ± 83.32, p = 0.129). Conclusion. Patients with longer SLE duration have more often MetS. It has been shown that, statistically, more patients without MetS were treated with antimalarial drugs monotherapy, and that long-term CS use, in our study, was not associated with higher incidence of MetS.
References
1.
Chan CT, Sobey CG, Lieu M, Ferens D, Kett MM, Diep H, et al. Obligatory Role for B Cells in the Development of Angiotensin II–Dependent Hypertension. Hypertension. 2015;66(5):1023–33.
2.
Petri M. Hydroxychloroquine use in the Baltimore Lupus Cohort: effects on lipids, glucose and thrombosis. Lupus. 1996;5(1_suppl):16–22.
3.
Ruiz-Irastorza G, Martín-Iglesias D, Soto-Peleteiro A. Update on antimalarials and systemic lupus erythematosus. Current Opinion in Rheumatology. 2020;32(6):572–82.
4.
Petri M, Lakatta C, Magder L, Goldman D. Effect of prednisone and hydroxychloroquine on coronary artery disease risk factors in systemic lupus erythematosus: A longitudinal data analysis. The American Journal of Medicine. 1994;96(3):254–9.
5.
Apostolopoulos D, Morand EF. It hasn’t gone away: the problem of glucocorticoid use in lupus remains. Rheumatology. :kew406.
6.
Svenungsson E, Fei GZ, Jensen-Urstad K, de Faire U, Hamsten A, Frostegård J. TNF-α: a link between hypertriglyceridaemia and inflammation in SLE patients with cardiovascular disease. Lupus. 2003;12(6):454–61.
7.
Urowitz MB, Gladman D, Ibañez D, Fortin P, Sanchez-Guerrero J, Bae S, et al. Clinical manifestations and coronary artery disease risk factors at diagnosis of systemic lupus erythematosus: data from an international inception cohort. Lupus. 2007;16(9):731–5.
8.
Szabó MZ, Szodoray P, Kiss E. Dyslipidemia in systemic lupus erythematosus. Immunologic Research. 2017;65(2):543–50.
9.
Petri M, Perez-Gutthann S, Spence D, Hochberg MC. Risk factors for coronary artery disease in patients with systemic lupus erythematosus. The American Journal of Medicine. 1992;93(5):513–9.
10.
Roman MJ, Shanker BA, Davis A, Lockshin MD, Sammaritano L, Simantov R, et al. Prevalence and Correlates of Accelerated Atherosclerosis in Systemic Lupus Erythematosus. New England Journal of Medicine. 2003;349(25):2399–406.
11.
Oeser A, Chung CP, Asanuma Y, Avalos I, Stein CM. Obesity is an independent contributor to functional capacity and inflammation in systemic lupus erythematosus. Arthritis & Rheumatism. 2005;52(11):3651–9.
12.
Mills JA. Systemic Lupus Erythematosus. New England Journal of Medicine. 1994;330(26):1871–9.
13.
Munguia-Realpozo P, Mendoza-Pinto C, Sierra Benito C, Escarcega RO, Garcia-Carrasco M, Mendez Martinez S, et al. Systemic lupus erythematosus and hypertension. Autoimmunity Reviews. 2019;18(10):102371.
14.
Manzi S, Meilahn EN, Rairie JE, Conte CG, Medsger TA, Jansen-McWilliams L, et al. Age-specific Incidence Rates of Myocardial Infarction and Angina in Women with Systemic Lupus Erythematosus: Comparison with the Framingham Study. American Journal of Epidemiology. 1997;145(5):408–15.
15.
Mok CC. Metabolic syndrome and systemic lupus erythematosus: the connection. Expert Review of Clinical Immunology. 2019;15(7):765–75.
16.
Petri M, Orbai A, Alarcón GS, Gordon C, Merrill JT, Fortin PR, et al. Derivation and validation of the Systemic Lupus International Collaborating Clinics classification criteria for systemic lupus erythematosus. Arthritis & Rheumatism. 2012;64(8):2677–86.
17.
Doria A, Shoenfeld Y, Wu R, Gambari PF, Puato M, Ghirardello A, et al. Risk factors for subclinical atherosclerosis in a prospective cohort of patients with systemic lupus erythematosus. Annals of the Rheumatic Diseases. 2003;62(11):1071–7.
18.
Sun C, Qin W, Zhang Y, Wu Y, Li Q, Liu M, et al. Prevalence and risk of metabolic syndrome in patients with systemic lupus erythematosus: A meta‐analysis. International Journal of Rheumatic Diseases. 2017;20(8):917–28.
19.
Huang PL. A comprehensive definition for metabolic syndrome. Disease Models & Mechanisms. 2009;2(5–6):231–7.
20.
Bozeman SR, Hoaglin DC, Burton TM, Pashos CL, Ben-Joseph RH, Hollenbeak CS. Predicting waist circumference from body mass index. BMC Medical Research Methodology. 2012;12(1).
21.
Skaggs BJ, Hahn BH, McMahon M. Accelerated atherosclerosis in patients with SLE—mechanisms and management. Nature Reviews Rheumatology. 2012;8(4):214–23.
The statements, opinions and data contained in the journal are solely those of the individual authors and contributors and not of the publisher and the editor(s). We stay neutral with regard to jurisdictional claims in published maps and institutional affiliations.
,
